Advances in cancer immunotherapy have offered new hope for patients with metastatic
disease. This unfolding success story has been exemplified by a growing arsenal of novel
immunotherapeutics, including blocking antibodies targeting immune checkpoint pathways,
cancer vaccines, and adoptive cell therapy (ACT). Nonetheless, clinical benefit remains
highly variable and patient-specific, in part, because all immunotherapeutic regimens vitally
hinge on the capacity of endogenous and/or adoptively transferred T-effector (T eff) cells …